ArticleSerican journal of medicine2025
Mechanisms and Therapeutic Strategies to Overcome Enzalutamide Resistance in Advanced Prostate Cancer.
Article in Serican journal of medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Enzalutamide, a second-generation androgen receptor (AR) inhibitor, has significantly improved survival outcomes in patients with metastatic castration-resistant prostate cancer (mCRPC). However, resistance to enzalutamide emerges in nearly all patients, posing a major clinical challenge. This review comprehensively examines the multifaceted mechanisms underlying enzalutamide resistance, including AR amplification, point mutations, splice variants such as AR-V7, and the activation of bypass signaling pathways, including glucocorticoid receptor signaling, PI3K/Akt/mTOR, and Wnt signaling. Additionally, the tumor microenvironment, lineage plasticity, and neuroendocrine differentiation contribute to therapy resistance through immune evasion and epigenetic reprogramming. We further discuss promising therapeutic strategies aimed at overcoming resistance, including combination treatments with PARP inhibitors, epigenetic modulators, and next-generation androgen receptor (AR) inhibitors. Biomarkers and personalized medicine approaches increasingly guide ongoing clinical trials to optimize treatment efficacy. This review also highlights drug repurposing as a practical avenue for targeting noncanonical vulnerabilities in resistant prostate cancer. Together, these insights provide a foundation for developing more durable and individualized treatment strategies for patients with enzalutamide-resistant metastatic castration-resistant prostate cancer (mCRPC).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.